drugset

drugset / Trial / NCT00580931

Safety Study of Nicotinamide to Treat Alzheimer's Disease

NCT00580931 ↗

Phase 1/2 Completed 50 enrolled University of California, Irvine Alzheimer's Association · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether nicotinamide, or vitamin B3, is safe and effective in the treatment of Alzheimer's disease.

Timeline

Start: 2008-01
Primary completion: 2014-07
Completion: 2014-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nicotinamide	Other / unclassified	1500 mg	—

Indications